This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Glaucoma  • Alert me on articles by topic

The GLC1C Locus

Frank W. Rozsa, PhD; Kathleen M. Scott, BS; Hemant Pawar, PhD; John R. Samples, MD; Mary K. Wirtz, PhD; Julia E. Richards, PhD

Arch Ophthalmol. 2007;125(1):117-127.

Objectives  To develop and apply a model for prioritization of candidate glaucoma genes.

Methods  This Affymetrix GeneChip (Affymetrix, Santa Clara, Calif) study of gene expression in primary culture human trabecular meshwork cells uses a positional differential expression profile model for prioritization of candidate genes within the GLC1C genetic inclusion interval.

Results  Sixteen genes were expressed under all conditions within the GLC1C interval. TMEM22 was the only gene within the interval with differential expression in the same direction under both conditions tested. Two genes, ATP1B3 and COPB2, are of interest in the context of a protein-misfolding model for candidate selection. SLC25A36, PCCB, and FNDC6 are of lesser interest because of moderate expression and changes in expression. Transcription factor ZBTB38 emerges as an interesting candidate gene because of the overall expression level, differential expression, and function.

Conclusions  Only 1 gene in the GLC1C interval fits our model for differential expression under multiple glaucoma risk conditions. The use of multiple prioritization models resulted in filtering 7 candidate genes of higher interest out of the 41 known genes in the region.

Clinical Relevance  This study identified a small subset of genes that are most likely to harbor mutations that cause glaucoma linked to GLC1C.

Author Affiliations: Departments of Ophthalmology and Visual Sciences (Drs Rozsa, Pawar, and Richards and Ms Scott) and Epidemiology (Dr Richards), University of Michigan, Ann Arbor; and Department of Ophthalmology, Oregon Health and Science University, Portland (Drs Samples and Wirtz).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Timolol on MYOC, OPTN, and WDR36 RNA Levels
Rozsa et al.
Arch Ophthalmol 2008;126:86-93.
ABSTRACT | FULL TEXT